Welcome to our dedicated page for Bristol-Myers Squibb Co SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bristol Myers Squibb (NYSE: BMY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings help investors understand how a global biopharmaceutical company in pharmaceutical preparation manufacturing manages its capital structure, reports financial results and communicates material events.
Recent Form 8-K filings from Bristol-Myers Squibb Company cover a range of topics. Some 8-Ks furnish quarterly earnings press releases and accompanying investor presentations, giving detail on financial performance and operating initiatives. Others describe the issuance of euro-denominated senior notes by a wholly owned Irish subsidiary, fully and unconditionally guaranteed by the company, including the terms of the notes, the governing indenture and the intended use of proceeds for tender offers and other corporate purposes. Additional 8-Ks outline cash tender offers for existing notes, early participation results, accepted amounts and pricing terms.
Filings also document corporate governance and executive matters, such as the departure of certain senior executives and related compensation arrangements, along with regular disclosures of dividend declarations. Regulation FD disclosures appear when the company posts investor presentations or updates on its website, and when it furnishes investor decks or webcasts tied to earnings calls and capital markets events.
On Stock Titan, these documents are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain the significance of complex filings, from debt offerings and tender offers to earnings releases and Regulation FD presentations. Users can quickly see what each filing covers, identify items related to capital markets activity, dividends or governance, and then drill into the full text when deeper analysis is needed. This page is a practical starting point for reviewing Bristol Myers Squibb’s official disclosures that may affect BMY stock and related securities, including its listed notes and Celgene contingent value rights.
Bristol Myers Squibb SVP and Controller Phil M. Holzer reported multiple equity award transactions in company stock and units on March 10, 2026. He exercised market share units and performance shares covering 6,191 shares of common stock and received new grants of 5,031 market share units and 7,547 performance share units under long-term incentive programs.
The filing shows vesting and performance-based adjustments to prior awards, along with 1,358 common shares withheld at $60.13 per share to cover tax obligations. Following these compensation-related transactions, Holzer directly holds 17,362 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb President, Cell Therapy Org. Lynelle Hoch reported multiple equity compensation transactions in company stock. On March 10, 2026, she exercised derivative awards, including market share units and performance shares, converting them into a total of 8,192 shares of common stock.
The filing also shows new grants of 6,531 market share units and 9,796 performance share units, each tied to future performance measurement periods and vesting dates through 2029. A total of 1,391 common shares were withheld at $60.13 per share to cover tax obligations upon vesting. Following these transactions, Hoch directly holds 8,210 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb executive Cari Gallman reported multiple equity-compensation transactions tied to prior and new long‑term incentive awards. On March 10, 2026, she exercised or converted derivative awards into a total of 6,980 shares of common stock, reflecting vesting of earlier market share units and performance shares granted in prior years.
The company withheld 2,165 shares at a price of $60.13 per share to cover tax obligations upon vesting, which is not an open‑market sale. Gallman also received new grants of 26,122 market share units and 39,184 performance share units that run through 2029, with payouts based on multi‑year stock price and performance formulas described in the award terms.
Bristol Myers Squibb executive vice president and chief people officer Amanda Poole Ahn reported several equity award events tied to performance-based compensation. On March 10, 2026, derivatives representing 6,436 shares of common stock were converted upon vesting of market share units and performance shares.
The company withheld 1,992 shares of common stock at $60.13 per share to cover tax obligations tied to these awards. Ahn also received new long-term incentives: 15,347 market share units and 23,020 performance share units, both scheduled to run to 2029 under performance-based payout structures.
Following these transactions, Ahn holds 7,094 shares of common stock directly and an additional 221.82 shares indirectly through the BMS Savings and Investment Program, reflecting routine compensation-related equity activity rather than open-market buying or selling.
Bristol Myers Squibb Chief Executive Officer Christopher S. Boerner reported multiple equity compensation transactions involving common stock and share units. On 2026-03-10, he exercised or settled 71,537 market share and performance share units into common stock and had 21,229 shares withheld at $60.13 per share to cover tax obligations and exercise costs.
He also received new long-term incentives, including 104,490 market share units and 156,735 performance share units that vest or convert based on multi-year performance conditions and Board certification. After these transactions, Boerner held 21,451 shares of common stock directly and 125,439 shares indirectly through a trust, reflecting compensation-related awards and routine tax withholding rather than open-market trading.
Bristol Myers Squibb EVP and CFO David V. Elkins reported a series of equity compensation transactions involving company stock. He exercised derivative awards, converting 62,982 market share units and performance shares into common stock on March 10, 2026, as previously granted awards vested under performance-based plans. He also received new grants of 35,265 market share units and 52,898 performance share units that will vest in future years based on performance and Board certification. To cover tax obligations on these vestings, 16,114 shares of common stock were withheld at a price of $60.13 per share, which is a non-market tax payment rather than an open-market sale. Following these transactions, Elkins directly holds 189,248 shares of common stock and has an additional 291.17 shares held indirectly through the BMS Savings and Investment Program.
Bristol Myers Squibb executive Benjamin Hickey, President of the RayzeBio organization, reported equity compensation activity involving restricted stock units and common stock. On February 27, 2026, 3,286 restricted stock units were exercised or converted into 3,286 shares of common stock at $0.00 per share as they vested. In connection with this vesting, 1,672 common shares were withheld at $62.37 per share to cover tax obligations, a non‑open‑market disposition. After these transactions, Hickey directly held 16,672 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, immunology, cardiovascular and neuroscience, generating $48,194 million in revenues for the year ended December 31, 2025, roughly flat versus 2024 and up from 2023.
The business is anchored by growth brands such as Opdivo, Eliquis, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati and Cobenfy, supported by broad patent and regulatory exclusivity across the U.S., EU and Japan. Legacy products including Revlimid, Pomalyst, Sprycel and Abraxane face generic erosion in key markets.
The company invested heavily in innovation, with $10.0 billion of R&D expense in 2025 and a pipeline of more than 45 assets across small molecules, biologics, ADCs, CAR-T and radiopharmaceuticals. New and expanded manufacturing facilities for cell therapies and radiopharmaceuticals were brought online in the U.S. and Europe.
Regulatory and pricing pressures are intensifying. Specific products, including Eliquis and Pomalyst, are subject to government-set Medicare prices under the Inflation Reduction Act, and Orencia has been selected for future “negotiation.” A 2025 agreement with the U.S. government adds further concessions, including providing Eliquis free to Medicaid and offering substantial direct-to-patient discounts on several brands.
Bristol-Myers Squibb Company furnished an update on its recent performance by issuing an earnings press release and investor presentation covering financial results for the fourth quarter of 2025 and the full year 2025.
The company posted the earnings press release and a “Bristol Myers Presentation” on its website in connection with an earnings conference call and webcast. Both materials include non-GAAP financial measures, with reconciliations and explanations provided in the press release. These materials are furnished, not filed, under the Exchange Act and are not automatically incorporated into future SEC filings.
Bristol Myers Squibb executive Gregory Scott Meyers reported equity compensation activity involving restricted stock units and common shares. On February 1, 2026, 2,543 restricted stock units vested and converted into 2,543 shares of common stock at an exercise price of $0, reflecting previously granted awards that vest annually in four equal installments beginning on February 1, 2023.
On the same date, 833 common shares were withheld at a price of $55.05 to cover taxes due upon vesting of the restricted stock units. After these transactions, Meyers directly owned 21,428 shares of Bristol Myers Squibb common stock.